Latest Schedule 13G passive stakes

Index Ventures entities have collectively reported beneficial ownership of 12.3% of Figma's Class A common stock, signaling substantial institutional confidence.

Tencent entities report updated beneficial ownership of Bilibili Inc. Class Z Ordinary Shares as of June 30, 2026.

Khrom Investments Fund, LP, Khrom Capital Management LLC, and Eric Khrom have collectively reported a beneficial ownership of 653,914 shares, representing 0.72% of Acadia Healthcare Company, Inc.

Tencent Holdings Ltd. and its subsidiary THL A12 Limited have reported an increased beneficial ownership of Horizon Quantum Holdings Ltd.'s Class A Ordinary Shares, now holding 11.1% of the outstanding shares.

Broad Bay Capital Management, LP has filed a Schedule 13G, disclosing beneficial ownership of 2,046,239 shares, representing 3.87% of the Series C Common Stock of Atlanta Braves Holdings, Inc.

Polar Capital Holdings Plc and Polar Capital LLP have reported beneficial ownership of 5.28% of Arcutis Biotherapeutics, Inc. common stock.

An amended Schedule 13G filing reveals updated beneficial ownership details for Ribbit Capital entities and Meyer Malka concerning Wealthfront Corp. common stock.

Tao Yang, Cheerio Investments Limited, and YooYoo Limited report combined beneficial ownership of 43.2% of Yalla Group Limited's Class A ordinary shares as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 5.3% of Beyond Air, Inc.'s common stock, including shares issuable upon warrant exercise.

Balyasny Asset Management L.P. and affiliated entities have filed an amendment to their Schedule 13G, reporting beneficial ownership of 6.43% of TXNM Energy, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and its affiliates have reported an increase in their beneficial ownership of Talkspace, Inc. common stock, now holding 4.09% of the outstanding shares.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 3,122,552 shares, representing 6.35% of SkyWater Technology, Inc.'s common stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 3,626,113 shares, representing 5.93% of Sagimet Biosciences Inc.'s common stock.

Balyasny Asset Management L.P. and affiliated entities have reported an adjustment in their beneficial ownership of SAB Biotherapeutics, Inc. common stock, now holding 9.45%.

Balyasny Asset Management L.P. and affiliated entities have filed a Schedule 13G, reporting beneficial ownership of 4.84% of Rezolute, Inc. common stock.

Balyasny Asset Management L.P. and affiliated entities have filed a Schedule 13G amendment, reporting zero shares beneficially owned in Rallybio Corp.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 500,000 shares, representing 6.43% of Research Alliance Corporation III's Class A Common Stock.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 9.99% of Quince Therapeutics, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 4.99% of Ovid Therapeutics Inc. common stock.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 9.99% of Nasus Pharma Ltd.'s common stock.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 818,706 shares, representing 5.18% of Neurogene Inc.'s common stock as of June 30, 2026.

Long Focus Capital Management, LLC and John Helmers report beneficial ownership of 6.0% of Standard BioTools Inc. common stock as of June 30, 2026.

Balyasny Asset Management and affiliated entities have disclosed beneficial ownership of 9.99% of Minerva Neurosciences' common stock, holding 4,654,212 shares.

Long Focus Capital Management, LLC and John Helmers report beneficial ownership of 4.9% of Aura Biosciences, Inc. common stock as of June 30, 2026.

Balyasny Asset Management L.P. and its affiliates have reported beneficial ownership of 9.99% of Lexeo Therapeutics, Inc. common stock, totaling 7,844,311 shares.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 951,783 shares, representing 6.6% of Korro Bio, Inc.'s common stock.

Balyasny Asset Management L.P. and affiliated entities have disclosed beneficial ownership of 500,000 shares, representing 6.23% of JATT II Acquisition Corp's common stock.

Balyasny Asset Management L.P. and affiliated entities have reported a beneficial ownership stake of 6.64% in Opus Genetics Inc., indicating a shift in institutional holding.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 6.97% of Helix Acquisition Corp. III's Class A Common Stock as of June 30, 2026.

Balyasny Asset Management L.P. and affiliated entities have reported beneficial ownership of 317,511 shares, representing 7.33% of Cyclerion Therapeutics, Inc. common stock.